BioPharmSignal logoBioPharmSignal

Biotech News

AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera

AN2 Therapeutics (ANTX)AN2 TherapeuticsFDA / regulatory

MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 2, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that the U.S.

Related news

ANTXAN2 Therapeutics2026-10-21 11:00 EST

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

ANTXAN2 Therapeutics2026-08-31 22:00 EST

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

ABUSArbutus2026-10-22 11:30 EST

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

ENTAEnanta Pharmaceuticals2026-06-23 09:10 EST

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus

SPROSpero Therapeutics2026-06-17 17:36 EST

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

SPROSpero Therapeutics2026-07-14 11:00 EST

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

ENTAEnanta Pharmaceuticals2026-10-28 11:00 EST

Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership

VIRIVirios Therapeutics2026-11-05 13:30 EST

Dogwood Therapeutics Announces Third Quarter 2026 Financial Results

ASMBAssembly Biosciences2026-10-05 14:00 EST

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

VIRIVirios Therapeutics2026-09-14 12:45 EST

Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial

View all latest news

AN2 Therapeutics

Boron-Based Drug Development AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning hematology, infectious disease, and oncology. Epetraborole in Polycythemia Vera AN2 is preparing the EBO-PV-201 Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent...

Recent company news

ANTXAN2 Therapeutics2026-11-04 21:00 EST

AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London

ANTXAN2 Therapeutics2026-11-04 12:00 EST

AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)

ANTXAN2 Therapeutics2026-11-02 12:00 EST

AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera

ANTXAN2 Therapeutics2026-10-23 21:00 EST

AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)

ANTXAN2 Therapeutics2026-10-21 11:00 EST

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

Stock data

Close
3.96 USD
Market cap
146.59M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States